Cellular therapy with stem cells is revolutionizing the focus of treatment of many serious diseases. Replacing the cells of damaged tissue with other new cells from the same patient is already a reality. This is the basis of cellular therapy and regenerative medicine, the latest great advance in biomedicine....
Stem Cell Treatment For Crohn’s Disease
Post-Operative Crohn’s Disease Recurrence May Be Prevented By Infliximab
The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn’s disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute....
New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohn’s Patients With Fistulizing Disease
Data presented this week by UCB at Advances in Inflammatory Bowel Diseases 2008, the Crohn’s & Colitis Foundation’s Clinical & Research Conference, demonstrated more than half (53.6%) of those moderate to severe Crohn’s disease patients who had open fistulas at baseline had...
Prometheus Presents New Clinical Insights Into Diagnosis Of Crohn’s Disease In Children From Analysis Of PROMETHEUS(R) IBD Serology 7 Test Results
Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings regarding the correlation between serologic markers and the diagnostic predictions of children with Crohn’s disease following an analysis of PROMETHEUS(R) IBD Serology 7 test results. Prometheus...
Abbott’s HUMIRA® (adalimumab) Data Shows Fistula Healing For Up To Three Years In Patients With Moderate To Severe Crohn’s Disease
New data showed that Abbott’s (NYSE: ABT) HUMIRA® (adalimumab) provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn’s disease experiencing fistula healing at three years, according to clinical research presented today at the United European...
Crohn’s Disease - Neovacs Begins A Phase I/II Clinical Trial With Candidate TNFα-kinoid, First Phase I/II Human Study Of A Kinoid
Neovacs, a leading biotechnology company in the development of anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases, announced that it had begun a phase I/II clinical study at three study centres in South Africa with the candidate TNFα-kinoid,...
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation In Crohn’s Disease Patients
Data from two studies presented this week by UCB at the American College of Gastroenterology (ACG) Annual Meeting demonstrate that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms with stable dosing for adult...
New Findings Show Efficacy Of REMICADE(R) Compared With Azathioprine In Treatment Of Crohn’s Disease According To First-of-its Kind Study
Data presented for the first time from the Phase 3b Study of Patients with Crohn’s Disease Naive to Immunomodulators and Biologic Therapy (SONIC) may provide new insights into the approach to care of patients with moderate to severe Crohn’s disease. According to findings from the SONIC trial,...
CIMZIA(R) (certolizumab Pegol) Reduces Intestinal Lesions And Induces Endoscopic Improvement In Crohn’s Patients
UCB presented data from a large, prospective study investigating endoscopic improvement in Crohn’s disease (CD) with a biologic compound. The data presented at the American College of Gastroenterology Annual Scientific Meeting demonstrates that CIMZIA(R) (certolizumab pegol) — the only PEGylated...
New Findings Show Efficacy Of REMICADE(R) Compared With Azathioprine In Treatment Of Crohn’s Disease According To First-of-its Kind Study
Data presented for the first time from the Phase 3b Study of Patients with Crohn’s Disease Naive to Immunomodulators and Biologic Therapy (SONIC) may provide new insights into the approach to care of patients with moderate to severe Crohn’s disease. According to findings from the SONIC trial,...